目的分析缺血性视网膜静脉阻塞继发黄斑水肿(RVO-ME)患者基线血清己糖激酶1抗体滴度与抗血管内皮生长因子(VEGF)治疗后视力改善的相关性。方法招募2017年6月至2020年2月在首都医科大学宣武医院确诊为缺血性RVO-ME并接受初始抗VEGF治疗...目的分析缺血性视网膜静脉阻塞继发黄斑水肿(RVO-ME)患者基线血清己糖激酶1抗体滴度与抗血管内皮生长因子(VEGF)治疗后视力改善的相关性。方法招募2017年6月至2020年2月在首都医科大学宣武医院确诊为缺血性RVO-ME并接受初始抗VEGF治疗的53例患者,其中缺血性视网膜中央静脉阻塞(CRVO)23例(CRVO组),缺血性视网膜分支静脉阻塞(BRVO)30例(BRVO组)。另选取该院同期30例行超声乳化的白内障患者作为对照组。研究对象行基线血清己糖激酶1抗体滴度检测、眼科常规检查和光学相干断层成像(OCT)检查。所有RVO-ME患者按照“3+按需治疗方案(pro re nata,PRN)”向玻璃体内注射抗VEGF药物治疗。随访12个月,采用多元线性回归分析缺血性RVO-ME患者抗VEGF治疗后视力改善的影响因素。结果CRVO组基线logMAR BCVA高于对照组和BRVO组,CRVO组和BRVO组基线CRT、基线血清己糖激酶1抗体滴度高于对照组,且CRVO组基线CRT、基线血清己糖激酶1抗体滴度高于BRVO组,差异有统计学意义(P<0.05)。RVO-ME患者基线血清己糖激酶1抗体滴度与随访6个月(r=0.377,P=0.005)、9个月(r=0.362,P=0.008)和12个月(r=0.465,P<0.001)时BCVA改善呈正相关,与随访12个月时中断EZ横向长度减少值(r=0.401,P=0.001)呈正相关。多元线性回归分析结果显示,基线logMAR BCVA、基线血清己糖激酶1抗体滴度是缺血性RVO-ME患者抗VEGF治疗随访12个月时BCVA改善的影响因素(P<0.05)。结论己糖激酶1抗体作为一种新的血清生物标志物,与缺血性RVO-ME患者抗VEGF治疗后的视力改善相关。展开更多
目的:评估玻璃体腔内注射地塞米松玻璃体内植入剂联合雷珠单抗注射液与单独使用雷珠单抗注射液在治疗视网膜静脉阻塞引起的黄斑水肿方面的疗效差异。方法:回顾性病例对照研究,本研究收集自2023年1月~2023年9月就诊于金川集团职工医院眼...目的:评估玻璃体腔内注射地塞米松玻璃体内植入剂联合雷珠单抗注射液与单独使用雷珠单抗注射液在治疗视网膜静脉阻塞引起的黄斑水肿方面的疗效差异。方法:回顾性病例对照研究,本研究收集自2023年1月~2023年9月就诊于金川集团职工医院眼科的静脉阻塞合并黄斑水肿(retinavein occlusion, RVO-ME)的患者114例(114只眼)的临床资料,根据治疗方式分为2组:每组各57例(57只眼),其中单药治疗组采用单独的玻璃体腔注射雷珠单抗进行治疗,联合治疗组采用雷珠单抗联合地塞米松玻璃体内植入剂进行玻璃体腔注射治疗。对比分析两组患者在治疗前及治疗后1、2、3和6个月的眼压、最佳矫正视力(Best corrected visual acuity, BCVA)以及黄斑中心凹视网膜厚度(central Retinal thickness, CRT)的变化情况。以期更全面地评估两种治疗方案的疗效和安全性。结果:组内比较:两组患者平均眼压、BCVA、CRT在术后不同时间点差异均有统计学意义(P P P P Objective: Further elucidating the comparative therapeutic effectiveness of intravitreal injection of a dexamethasone intravitreal implant in conjunction with ranibizumab injection, against the administration of ranibizumab alone, in addressing macular edema stemming from retinal vein occlusion. Method: Retrospective case control study This study collects clinical data of 114 patients with venous occlusion combined with macular edema (RVO-ME) who are admitted to the Ophthalmology Department of Jinchuan Group Staff Hospital from January 2023 to September 2023. They are divided into 2 groups according to treatment mode: There were 57 patients in each group (57 eyes), in which the monotherapy group was treated with single intravitreal injection of leizumab, and the combined treatment group was treated with intravitreal injection of leizumab combined with dexamethasone intravitreal implant. The changes of IOP, best corrected visual acuity (BCVA) and central Retinal thickness (CRT) in macular fovea were compared between the two groups before treatment and 1, 2, 3 and 6 months after treatment. In order to comprehensively evaluate the efficacy and safety of both treatment options. Results: There was no statistically significant difference in preoperative baseline data between the two groups of patients (P > 0.05);The results of repeated measures analysis of variance showed that there were statistically significant differences in mean intraocular pressure, BCVA, and CRT between the two groups of patients at different time points after surgery (P P P P < 0.05);Conclusions: Intravitreal injection of ranibizumab combined with dexamethasone in the treatment of RVO-ME can effectively improve the visual acuity of patients compared to the use of ranibizumab alone, with a longer duration of efficacy maintenance.展开更多
文摘目的分析缺血性视网膜静脉阻塞继发黄斑水肿(RVO-ME)患者基线血清己糖激酶1抗体滴度与抗血管内皮生长因子(VEGF)治疗后视力改善的相关性。方法招募2017年6月至2020年2月在首都医科大学宣武医院确诊为缺血性RVO-ME并接受初始抗VEGF治疗的53例患者,其中缺血性视网膜中央静脉阻塞(CRVO)23例(CRVO组),缺血性视网膜分支静脉阻塞(BRVO)30例(BRVO组)。另选取该院同期30例行超声乳化的白内障患者作为对照组。研究对象行基线血清己糖激酶1抗体滴度检测、眼科常规检查和光学相干断层成像(OCT)检查。所有RVO-ME患者按照“3+按需治疗方案(pro re nata,PRN)”向玻璃体内注射抗VEGF药物治疗。随访12个月,采用多元线性回归分析缺血性RVO-ME患者抗VEGF治疗后视力改善的影响因素。结果CRVO组基线logMAR BCVA高于对照组和BRVO组,CRVO组和BRVO组基线CRT、基线血清己糖激酶1抗体滴度高于对照组,且CRVO组基线CRT、基线血清己糖激酶1抗体滴度高于BRVO组,差异有统计学意义(P<0.05)。RVO-ME患者基线血清己糖激酶1抗体滴度与随访6个月(r=0.377,P=0.005)、9个月(r=0.362,P=0.008)和12个月(r=0.465,P<0.001)时BCVA改善呈正相关,与随访12个月时中断EZ横向长度减少值(r=0.401,P=0.001)呈正相关。多元线性回归分析结果显示,基线logMAR BCVA、基线血清己糖激酶1抗体滴度是缺血性RVO-ME患者抗VEGF治疗随访12个月时BCVA改善的影响因素(P<0.05)。结论己糖激酶1抗体作为一种新的血清生物标志物,与缺血性RVO-ME患者抗VEGF治疗后的视力改善相关。
文摘目的:评估玻璃体腔内注射地塞米松玻璃体内植入剂联合雷珠单抗注射液与单独使用雷珠单抗注射液在治疗视网膜静脉阻塞引起的黄斑水肿方面的疗效差异。方法:回顾性病例对照研究,本研究收集自2023年1月~2023年9月就诊于金川集团职工医院眼科的静脉阻塞合并黄斑水肿(retinavein occlusion, RVO-ME)的患者114例(114只眼)的临床资料,根据治疗方式分为2组:每组各57例(57只眼),其中单药治疗组采用单独的玻璃体腔注射雷珠单抗进行治疗,联合治疗组采用雷珠单抗联合地塞米松玻璃体内植入剂进行玻璃体腔注射治疗。对比分析两组患者在治疗前及治疗后1、2、3和6个月的眼压、最佳矫正视力(Best corrected visual acuity, BCVA)以及黄斑中心凹视网膜厚度(central Retinal thickness, CRT)的变化情况。以期更全面地评估两种治疗方案的疗效和安全性。结果:组内比较:两组患者平均眼压、BCVA、CRT在术后不同时间点差异均有统计学意义(P P P P Objective: Further elucidating the comparative therapeutic effectiveness of intravitreal injection of a dexamethasone intravitreal implant in conjunction with ranibizumab injection, against the administration of ranibizumab alone, in addressing macular edema stemming from retinal vein occlusion. Method: Retrospective case control study This study collects clinical data of 114 patients with venous occlusion combined with macular edema (RVO-ME) who are admitted to the Ophthalmology Department of Jinchuan Group Staff Hospital from January 2023 to September 2023. They are divided into 2 groups according to treatment mode: There were 57 patients in each group (57 eyes), in which the monotherapy group was treated with single intravitreal injection of leizumab, and the combined treatment group was treated with intravitreal injection of leizumab combined with dexamethasone intravitreal implant. The changes of IOP, best corrected visual acuity (BCVA) and central Retinal thickness (CRT) in macular fovea were compared between the two groups before treatment and 1, 2, 3 and 6 months after treatment. In order to comprehensively evaluate the efficacy and safety of both treatment options. Results: There was no statistically significant difference in preoperative baseline data between the two groups of patients (P > 0.05);The results of repeated measures analysis of variance showed that there were statistically significant differences in mean intraocular pressure, BCVA, and CRT between the two groups of patients at different time points after surgery (P P P P < 0.05);Conclusions: Intravitreal injection of ranibizumab combined with dexamethasone in the treatment of RVO-ME can effectively improve the visual acuity of patients compared to the use of ranibizumab alone, with a longer duration of efficacy maintenance.
